Active substance
Results for the substance serplulimab
1 result
About this active substance
Serplulimab is a humanized monoclonal antibody used in the treatment of certain types of cancer. It is a programmed death-1 (PD-1) receptor inhibitor, a protein that plays a key role in regulating the immune response. By blocking PD-1, serplulimab helps the immune system recognize and destroy cancer cells, making it a key agent in cancer immunotherapy.
The mechanism of action of serplulimab involves inhibiting the interaction between PD-1 and its ligands (PD-L1 and PD-L2), which are often overexpressed on tumor cells. This interaction suppresses T-cell activity, allowing tumors to evade immune attack. By blocking PD-1, serplulimab reactivates T-cells, enhancing the immune response against tumors.
Serplulimab is indicated for the treatment of certain cancers, such as lung cancer, gastric cancer, or other solid tumors, depending on PD-L1 expression and other molecular characteristics of the tumor. It is administered intravenously, according to a protocol established by an oncologist, and may be used alone or in combination with other cancer therapies.
While effective, serplulimab can cause side effects, including immune-related adverse events. The most common include fatigue, nausea, diarrhea, rash, and itching. In rare cases, severe adverse events such as pneumonitis, hepatitis, colitis, or autoimmune endocrinopathies may occur. It is essential for patients to be closely monitored during treatment to detect and manage potential complications promptly.
The mechanism of action of serplulimab involves inhibiting the interaction between PD-1 and its ligands (PD-L1 and PD-L2), which are often overexpressed on tumor cells. This interaction suppresses T-cell activity, allowing tumors to evade immune attack. By blocking PD-1, serplulimab reactivates T-cells, enhancing the immune response against tumors.
Serplulimab is indicated for the treatment of certain cancers, such as lung cancer, gastric cancer, or other solid tumors, depending on PD-L1 expression and other molecular characteristics of the tumor. It is administered intravenously, according to a protocol established by an oncologist, and may be used alone or in combination with other cancer therapies.
While effective, serplulimab can cause side effects, including immune-related adverse events. The most common include fatigue, nausea, diarrhea, rash, and itching. In rare cases, severe adverse events such as pneumonitis, hepatitis, colitis, or autoimmune endocrinopathies may occur. It is essential for patients to be closely monitored during treatment to detect and manage potential complications promptly.